After Long Wait, Zytiga To Boost J&J’s China Oncology Presence
This article was originally published in PharmAsia News
Previously a symbol of China's drug lag problems, Zytiga is finally available to increasing numbers of prostate cancer patients in the country, seven months after J&J's local pharmaceutical subsidiary Xian Janssen obtained a regulatory nod from the China FDA. But without initial reimbursement coverage, J&J is depending on patient assistance programs to expand drug access.
You may also be interested in...
As China tightens its grip over clinical research using human genetic data in the country, and the US increases scrutiny over the use of personal data, multinational drug developers may face a difficult choice or even create separate entities to cater to local regulatory requirements. WuXi NextCODE provides one interesting case study.
Amid a sweeping National Security Law passage, many biotech and healthcare firms from China opt for a Hong Kong initial public offering in the meanwhile appetite for a US listing wanes.
The move may signal China is accelerating the vaccine to hit the general market soon, but a false impression of the vaccine’s safety may be potentially misleading, says one regulatory expert.